This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Immunology

MSD immunology is proud to be at the forefront of patient care and remains committed to helping patients overcome the burden of debilitating chronic diseases now and in the future.

MSD has two widely used anti-TNF (Tumour Necrosis Factor) products with licences across three therapeutic areas: Gastroenterology, Rheumatology and Dermatology.1,2

SIMPONI (golimumab) is the first and only subcutaneous anti-TNF therapy with convenient once-monthly dosing from day 1 for Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Non-Radiographic Axial Spondyloarthritis (Nr-axSpA) and a 4-weekly dosing schedule for Ulcerative Colitis (UC).1

Gastroenterology

Find out how SIMPONI can help your patients with moderate-severe Ulcerative Colitis.

Find out more

Rheumatology

Find out how SIMPONI can help your patients with AS, PsA, nr-axSpA, and RA.

Find out more
Indications

Important safety information

REMICADE is a monoclonal antibody; it is a TNFα (Tumour Necrosis Factor–alpha) inhibitor that is indicated for the treatment of a range of immune-mediated inflammatory disorders.2

Indications

REMICADE is a prescription-only product. It is presented as powder (100 mg/vial) to be reconstituted with water, diluted with saline and thereafter administered via intravenous infusion.2

Remicade

Visit the REMICADE page to learn more

Find out more

References

  1. SIMPONI® (golimumab). Summary of Product Characteristics.
  2. REMICADE 100 mg powder for concentrate for solution for infusion Summary of Product Characteristics.

GB-GOL-00380 | Date of Preparation: December 2020